Source: Healio News
Chimeric antigen receptor T-cell therapy has induced exceptional response rates among patients with relapsed or refractory multiple myeloma compared with conventional options, according to a speaker at Chemotherapy Foundation Symposium.
Shambavi Richard, MD, assistant professor of medicine, hematology and medical oncology at Icahn School of Medicine at Mount Sinai, compared immunotherapy approaches to treat patients with triple-class refractory multiple myeloma and concluded that two CAR T-cell therapies so far have shown unmatched efficacy.
The 98% percent overall response rate for